Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era

Whether to clinically approach follicular lymphoma (FL) grade 3 as an indolent or aggressive lymphoma, especially since the introduction of rituximab, is unclear. Our experience with FL grade 3A, compared with FL grade 3B or with concomitant diffuse large B cell lymphoma, primarily treated with R-CHOP suggests possible long-term remissions. This must be confirmed with longer follow-up and additional studies.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Moaath Mustafa Ali, Lisa Rybicki, Laila Nomani, Basel Rouphail, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Eric D. Hsi, Mitchell R. Smith Source Type: research